{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T07:43:12Z","timestamp":1648885392339},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s11657-015-0233-4","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T10:16:44Z","timestamp":1447928204000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comorbidities, bone-sparing agent prescription history and their determinants among postmenopausal women in UK primary care settings: a retrospective database study"],"prefix":"10.1007","volume":"10","author":[{"given":"M.","family":"Feudjo-Tepie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Roddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bayly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Critchlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"key":"233_CR1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/BF01880454","volume":"1","author":"R Bouillon","year":"1991","unstructured":"Bouillon R, Burkhardt P, Christiansen C, Fleisch HA, Fujita T, Gennari C, Martin TJ, Mazzuoli G, Melton LJ, Ringe JD (1991) Consensus development conference: prophylaxis and treatment of osteoporosis. Osteoporos Int 1:114\u2013117","journal-title":"Osteoporos Int"},{"key":"233_CR2","unstructured":"Scottish Intercollegiate Guidelines Network (2003) National Clinical Guideline 71: Management of osteoporosis. Available at: http:\/\/www.sign.ac.uk\/pdf\/sign71.pdf . Accessed July 2014"},{"key":"233_CR3","first-page":"293","volume":"7","author":"American Association of Clinical Endocrinologists Osteoporosis Task Force","year":"2001","unstructured":"American Association of Clinical Endocrinologists Osteoporosis Task Force (2001) American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 7:293\u2013312","journal-title":"Endocr Pract"},{"key":"233_CR4","unstructured":"International Osteoporosis Foundation (2012) Europe guidelines. Available at: http:\/\/www.iofbonehealth.org\/europe-guidelines . Accessed 30 April 2014"},{"key":"233_CR5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399\u2013428","journal-title":"Osteoporos Int"},{"key":"233_CR6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","volume":"18","author":"A Cramer","year":"2007","unstructured":"Cramer A, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023\u20131031","journal-title":"Osteoporos Int"},{"key":"233_CR7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"233_CR8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","volume":"27","author":"GY Boivin","year":"2000","unstructured":"Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687\u2013694","journal-title":"Bone"},{"key":"233_CR9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"233_CR10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"JY Reginster","year":"2000","unstructured":"Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"233_CR11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13697130500118126","volume":"8","author":"MJ Hooper","year":"2005","unstructured":"Hooper MJ, Ebeling PR, Roberts AP (2005) Risedronate prevents bone loss in early postmenopausal women: a prospective, randomized controlled trial. Climacteric 8:251\u2013262","journal-title":"Climacteric"},{"key":"233_CR12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata Y, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u2013468","journal-title":"N Engl J Med"},{"key":"233_CR13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453\u20131460","journal-title":"Curr Med Res Opin"},{"key":"233_CR14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","volume":"48","author":"JS McCombs","year":"2004","unstructured":"McCombs JS, Thibaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271\u2013287","journal-title":"Maturitas"},{"key":"233_CR15","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00198-010-1372-5","volume":"22","author":"JC Netelenbos","year":"2011","unstructured":"Netelenbos JC, Geusens PP, Ypma G, Buijs SJ (2011) Adherence and profile of non-persistence in patients treated for osteoporosis\u2014a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 22:1537\u20131546","journal-title":"Osteoporos Int"},{"key":"233_CR16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223\u2013231","journal-title":"Osteoporos Int"},{"key":"233_CR17","doi-asserted-by":"crossref","first-page":"596","DOI":"10.18553\/jmcp.2011.17.8.596","volume":"17","author":"KE Martin","year":"2011","unstructured":"Martin KE, Yu J, Campbell HE, Abarca J, White TJ (2011) Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. J Manag Care Pharm 17:596\u2013609","journal-title":"J Manag Care Pharm"},{"key":"233_CR18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/pds.1634","volume":"17","author":"F Hoffmann","year":"2008","unstructured":"Hoffmann F, Jung TI, Felsenberg D, Glaeske G (2008) Pattern of intravenous bisphosphonate use in outpatient care in Germany. Pharmacoepidemiol Drug Saf 17:896\u2013903","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"233_CR19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-007-0455-4","volume":"19","author":"SA Foster","year":"2007","unstructured":"Foster SA, Foley KA, Meadows ES, Johnston JA, Wang S, Pohl GM, Long SR (2007) Characteristics of patients initiating teriparatide for the treatment of osteoporosis. Osteoporos Int 19:373\u2013377","journal-title":"Osteoporos Int"},{"key":"233_CR20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.amjmed.2009.05.017","volume":"123","author":"BA Briesacher","year":"2010","unstructured":"Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA (2010) Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med 123:275\u2013280","journal-title":"Am J Med"},{"key":"233_CR21","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00198-009-1046-3","volume":"21","author":"A Abelson","year":"2010","unstructured":"Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T (2010) Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int 21:1021\u20131029","journal-title":"Osteoporos Int"},{"key":"233_CR22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00223-007-9066-5","volume":"81","author":"ET Middleton","year":"2007","unstructured":"Middleton ET, Steel SA, Doherty SM (2007) The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice. Calcif Tissue Int 81:335\u2013340","journal-title":"Calcif Tissue Int"},{"key":"233_CR23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/qjmed\/91.6.445","volume":"91","author":"DH Lawson","year":"1998","unstructured":"Lawson DH, Sherman V, Hollowell J (1998) The general practice research database for the scientific and ethical advisory group. Q J Med 91:445\u2013452","journal-title":"Q J Med"},{"key":"233_CR24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2125.1998.00701.x","volume":"45","author":"LA Garcia Rodriguez","year":"1998","unstructured":"Garcia Rodriguez LA, Perez Gutthann S (1998) Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 45:419\u2013425","journal-title":"Br J Clin Pharmacol"},{"key":"233_CR25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1359\/jbmr.080510","volume":"23","author":"A Gallagher","year":"2008","unstructured":"Gallagher A, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related persistence and compliance with oral bisphosphonate. J Bone Miner Res 23:1569\u20131575","journal-title":"J Bone Miner Res"},{"key":"233_CR26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/qjmed\/hcn130","volume":"102","author":"S Rietbrock","year":"2009","unstructured":"Rietbrock S, Olson M, van Staa TP (2009) The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. Q J Med 102:35\u201342","journal-title":"Q J Med"},{"key":"233_CR27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/pds.2630010607","volume":"1","author":"H Jick","year":"1992","unstructured":"Jick H, Terris BZ, Derby LE, Jick SS (1992) Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1:347\u2013349","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"233_CR28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(97)04248-7","volume":"350","author":"T Walley","year":"1997","unstructured":"Walley T, Mantgani A (1997) The UK general practice research database. Lancet 350:1097\u20131099","journal-title":"Lancet"},{"key":"233_CR29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/0081-1750.t01-1-00075","volume":"30","author":"A Agresti","year":"2008","unstructured":"Agresti A, Booth J, Hobert JP, Caffo B (2008) Random-effects modeling of categorical response data. Sociol Methodol 30:27\u201380","journal-title":"Sociol Methodol"},{"key":"233_CR30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2006.01.002","volume":"28","author":"FJ Penning-van Beest","year":"2006","unstructured":"Penning-van Beest FJ, Goettsh WG, Erkens JA, Herings RM (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28:236\u2013242","journal-title":"Clin Ther"},{"key":"233_CR31","unstructured":"National Institute for Health and Care Excellence (2011) TA160 Osteoporosis \u2013 primary prevention. Available at: http:\/\/guidance.nice.org.uk\/TA160 . Accessed 30 April 2014"},{"key":"233_CR32","unstructured":"National Institute for Health and Care Excellence (2011) TA161 Osteoporosis \u2013 secondary prevention. Available at: http:\/\/www.nice.org.uk\/guidance\/ta161\/resources\/ta161-osteoporosis-secondary-prevention-including-strontium-ranelate-understanding-nice-guidance2 . Accessed 30 April 2014"},{"key":"233_CR33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.18553\/jmcp.2004.10.2.142","volume":"10","author":"NB Watts","year":"2004","unstructured":"Watts NB, Worley K, Solis A, Doyle J, Sheer R (2004) Comparison of risedronate to alendonate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 10:142\u2013152","journal-title":"J Manag Care Pharm"},{"key":"233_CR34","unstructured":"National Institute for Health and Care Excellence (2014) Osteoporosis overview. Available at: http:\/\/pathways.nice.org.uk\/pathways\/osteoporosis#content=view-node%3Anodes-secondary-prevention-of-osteoporotic-fragility-fractures-in-postmenopausal-women . Accessed 20 July 2015."},{"key":"233_CR35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1378\/chest.121.2.609","volume":"121","author":"DM Biskobing","year":"2002","unstructured":"Biskobing DM (2002) COPD and osteoporosis. Chest 121:609\u2013620","journal-title":"Chest"},{"key":"233_CR36","unstructured":"Royal College of Physicians (2011) Falling standards, broken promises: report of the national audit of falls and bone health in older people 2010. Available at: https:\/\/www.rcplondon.ac.uk\/sites\/default\/files\/national_report.pdf . Accessed 20 July 2015"},{"key":"233_CR37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2147\/IJGM.S36944","volume":"6","author":"A Balasubramanian","year":"2013","unstructured":"Balasubramanian A, Brookhart MA, Goli V, Critchlow CW (2013) Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med 6:839\u2013848","journal-title":"Int J Gen Med"},{"key":"233_CR38","doi-asserted-by":"crossref","unstructured":"Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Treatment of Osteoporosis in clinical Practice (TOP) Study Group (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 914","DOI":"10.1007\/s00198-006-0073-6"},{"key":"233_CR39","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1210\/jc.2006-1856","volume":"92","author":"J Blouin","year":"2007","unstructured":"Blouin J, Dragomir A, Ste-Marie L, Fernandes JC, Perreault S (2007) Discontinuation of antiresorptive therapies: a comparison between 1998\u20132001 and 2002\u20132004 among osteoporotic women. J Clin Endocrinol Metab 92:887\u2013894","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR40","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s00198-006-0085-2","volume":"17","author":"JC Lo","year":"2006","unstructured":"Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922\u2013928","journal-title":"Osteoporos Int"},{"key":"233_CR41","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","volume":"165","author":"DH Solomon","year":"2005","unstructured":"Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414\u20132419","journal-title":"Arch Intern Med"},{"key":"233_CR42","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bone.2012.02.639","volume":"50","author":"EM Dennison","year":"2013","unstructured":"Dennison EM, Compston JE, Flahive J et al (2013) Effect of comorbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 50:1288\u20131293","journal-title":"Bone"},{"key":"233_CR43","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2215\/CJN.06300613","volume":"8","author":"KE Ensrud","year":"2013","unstructured":"Ensrud KE (2013) Fracture risk in CKD. Clin J Am Soc Nephrol 8:1282\u20131283","journal-title":"Clin J Am Soc Nephrol"},{"key":"233_CR44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/bmj.307.6895.32","volume":"307","author":"I Nazareth","year":"1993","unstructured":"Nazareth I, King M, Haines A, Rangel L, Myers S (1993) Accuracy of diagnosis on general practice computer system. BMJ 307:32\u201334","journal-title":"BMJ"},{"key":"233_CR45","unstructured":"Hippisley-Cox J, Bayly J, Potter J, Fenty J, Parker C. Evaluation of standards of care for osteoporosis and falls in primary care. 2007. Available at: http:\/\/www.ic.nhs.uk\/statistics-and-data-collections\/primary-care\/general-practice\/evaluation-of-standards-of-care-for-osteoporosis-and-falls-in-primary-care . Accessed 30 April 2015"},{"key":"233_CR46","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1742-1241.2009.02206.x","volume":"63","author":"S Boonen","year":"2009","unstructured":"Boonen S, Kay R, Cooper C, Haentjens P, Vanderschueren D, Callewaert F, Milisen K (2009) Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. Int J Clin Pract 63:1792\u20131804","journal-title":"Int J Clin Pract"},{"key":"233_CR47","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1023\/A:1021235123382","volume":"17","author":"JB Soriano","year":"2001","unstructured":"Soriano JB, Maier WC, Visick G, Pride NB (2001) Validation of general practitioner-diagnosed COPD in the UK general practice research database. Eur J Epidemiol 17:1075\u20131080","journal-title":"Eur J Epidemiol"},{"key":"233_CR48","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/GME.0000000000000214","volume":"21","author":"L Li","year":"2014","unstructured":"Li L, Roddam A, Ferguson S, Feudjo-Tepie M, Taylor A, Jick S (2014) Switch patterns of osteoporosis medication and its impact on persistence among postmenopausal women in the U.K. General Practice Research Database. Menopause 21:1106\u20131113","journal-title":"Menopause"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-015-0233-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11657-015-0233-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-015-0233-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T15:32:41Z","timestamp":1599838361000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11657-015-0233-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["233"],"URL":"https:\/\/doi.org\/10.1007\/s11657-015-0233-4","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]},"article-number":"41"}}